AVD 1001
Alternative Names: AVD-1001Latest Information Update: 28 Oct 2024
Price :
$50 *
At a glance
- Originator Aviceda Therapeutics
- Class Hepatoprotectants
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Liver disorders
Most Recent Events
- 28 Oct 2024 No recent reports of development identified for preclinical development in Liver-disorders in USA (Parenteral)
- 21 Sep 2020 AVD 1001 is available for licensing as of 21 Sep 2020. https://www.avicedarx.com/
- 21 Sep 2020 Preclinical trials in Liver disorders in USA (Parenteral), prior to September 2020 (Aviceda Therapeutics pipeline, September 2020)